Joseph Catanzaro
Stock Analyst at Mizuho Securities
(4.60)
# 940
Out of 4,996 analysts
419
Total ratings
45.8%
Success rate
12.2%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTX Avalo Therapeutics | Rated: Hold | n/a | $15.30 | - | 4 | Sep 4, 2026 | |
| BCAX Bicara Therapeutics | Rated: Hold | n/a | $20.49 | - | 3 | Sep 4, 2026 | |
| CLDX Celldex Therapeutics | Rated: Hold | n/a | $31.12 | - | 4 | Sep 4, 2026 | |
| ERAS Erasca | Rated: Hold | n/a | $13.95 | - | 5 | Sep 4, 2026 | |
| KYMR Kymera Therapeutics | Rated: Hold | n/a | $115.47 | - | 4 | Sep 4, 2026 | |
| NRIX Nurix Therapeutics | Rated: Hold | n/a | $23.88 | - | 28 | Sep 4, 2026 | |
| RVMD Revolution Medicines | Rated: Hold | n/a | $190.74 | - | 18 | Sep 4, 2026 | |
| SYRE Spyre Therapeutics | Rated: Hold | n/a | $88.17 | - | 5 | Sep 4, 2026 | |
| TNGX Tango Therapeutics | Rated: Hold | n/a | $24.45 | - | 10 | Sep 4, 2026 | |
| UPB Upstream Bio | Rated: Hold | n/a | $5.19 | - | 3 | Sep 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 → $36 | $9.56 | +276.57% | 2 | Jul 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $50 | $15.73 | +217.86% | 1 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $12.52 | +43.77% | 1 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $26 | $8.13 | +219.80% | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4.5 | $0.3826 | n/a | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 → $38 | $3.76 | n/a | 5 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3.25 | $2.78 | n/a | 15 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $53 | $112.44 | n/a | 27 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4.75 → $4.25 | $8.63 | n/a | 15 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.31 | n/a | 16 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7.5 → $6 | $10.19 | n/a | 37 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 → $45 | $29.23 | n/a | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 → $38 | $56.73 | n/a | 11 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $105 → $110 | $151.37 | n/a | 20 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 → $3 | $3.61 | n/a | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 → $15 | $11.63 | n/a | 25 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $19 | $8.60 | n/a | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $19 | $1.44 | n/a | 17 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 | $1.90 | n/a | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 | $2.06 | n/a | 8 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $8 | $1.53 | n/a | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $1.75 | $3.82 | n/a | 9 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $2.72 | n/a | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $10.00 | n/a | 39 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $1.75 | $1.01 | n/a | 8 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.5 → $1.75 | $1.07 | n/a | 4 | Sep 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $1.24 | n/a | 3 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $30.93 | n/a | 4 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $4 | $31.55 | n/a | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 → $36 | $11.97 | n/a | 4 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 → $17 | $1.31 | n/a | 7 | Aug 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 → $18 | $2.18 | n/a | 4 | Apr 7, 2020 |
Avalo Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $15.30
Upside: -
Bicara Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $20.49
Upside: -
Celldex Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $31.12
Upside: -
Erasca
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $13.95
Upside: -
Kymera Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $115.47
Upside: -
Nurix Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $23.88
Upside: -
Revolution Medicines
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $190.74
Upside: -
Spyre Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $88.17
Upside: -
Tango Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $24.45
Upside: -
Upstream Bio
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $5.19
Upside: -
Jul 13, 2026
Reiterated: Buy
Price Target: $14 → $36
Current: $9.56
Upside: +276.57%
Apr 30, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $15.73
Upside: +217.86%
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $12.52
Upside: +43.77%
Mar 2, 2026
Initiated Coverage: Buy
Price Target: $26
Current: $8.13
Upside: +219.80%
Mar 21, 2025
Reiterated: Buy
Price Target: $4.5
Current: $0.3826
Upside: n/a
Mar 20, 2025
Reiterated: Buy
Price Target: $36 → $38
Current: $3.76
Upside: n/a
Mar 7, 2025
Reiterated: Buy
Price Target: $3.25
Current: $2.78
Upside: n/a
Mar 6, 2025
Reiterated: Hold
Price Target: $53
Current: $112.44
Upside: n/a
Mar 3, 2025
Reiterated: Hold
Price Target: $4.75 → $4.25
Current: $8.63
Upside: n/a
Feb 28, 2025
Reiterated: Buy
Price Target: $10
Current: $1.31
Upside: n/a
Feb 28, 2025
Reiterated: Hold
Price Target: $7.5 → $6
Current: $10.19
Upside: n/a
Feb 27, 2025
Reiterated: Buy
Price Target: $50 → $45
Current: $29.23
Upside: n/a
Feb 12, 2025
Reiterated: Buy
Price Target: $37 → $38
Current: $56.73
Upside: n/a
Feb 12, 2025
Reiterated: Buy
Price Target: $105 → $110
Current: $151.37
Upside: n/a
Jan 29, 2025
Rated: Buy
Price Target: $15 → $3
Current: $3.61
Upside: n/a
Jan 17, 2025
Reiterated: Buy
Price Target: $40 → $15
Current: $11.63
Upside: n/a
Nov 6, 2024
Rated: Buy
Price Target: $19
Current: $8.60
Upside: n/a
Oct 31, 2024
Reiterated: Buy
Price Target: $10 → $19
Current: $1.44
Upside: n/a
Oct 8, 2024
Rated: Buy
Price Target: $15
Current: $1.90
Upside: n/a
Sep 16, 2024
Rated: Buy
Price Target: $30
Current: $2.06
Upside: n/a
Sep 16, 2024
Reiterated: Buy
Price Target: $10 → $8
Current: $1.53
Upside: n/a
Aug 27, 2024
Downgraded: Hold
Price Target: $5 → $1.75
Current: $3.82
Upside: n/a
Apr 22, 2024
Initiated Coverage: Buy
Price Target: $20
Current: $2.72
Upside: n/a
Apr 8, 2024
Reiterated: Buy
Price Target: $15
Current: $10.00
Upside: n/a
May 23, 2023
Downgraded: Hold
Price Target: $15 → $1.75
Current: $1.01
Upside: n/a
Sep 14, 2022
Reiterated: Hold
Price Target: $1.5 → $1.75
Current: $1.07
Upside: n/a
May 31, 2022
Reiterated: Buy
Price Target: $15
Current: $1.24
Upside: n/a
May 31, 2022
Reiterated: Buy
Price Target: $6
Current: $30.93
Upside: n/a
May 12, 2022
Reiterated: Buy
Price Target: $10 → $4
Current: $31.55
Upside: n/a
Mar 9, 2022
Reiterated: Buy
Price Target: $45 → $36
Current: $11.97
Upside: n/a
Aug 21, 2020
Reiterated: Buy
Price Target: $15 → $17
Current: $1.31
Upside: n/a
Apr 7, 2020
Reiterated: Buy
Price Target: $28 → $18
Current: $2.18
Upside: n/a